Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Protalix BioTherapeutics (PLX) over the last 13 years, with Q1 2025 value amounting to $6000.0.

  • Protalix BioTherapeutics' Interest Expenses fell 9846.15% to $6000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $47000.0, marking a year-over-year decrease of 9739.32%. This contributed to the annual value of $1.1 million for FY2024, which is 6660.38% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Interest Expenses stood at $6000.0 for Q1 2025, which was down 9846.15% from $41000.0 recorded in Q4 2024.
  • Protalix BioTherapeutics' 5-year Interest Expenses high stood at $2.4 million for Q3 2021, and its period low was $6000.0 during Q1 2025.
  • In the last 5 years, Protalix BioTherapeutics' Interest Expenses had a median value of $639000.0 in 2022 and averaged $851235.3.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Interest Expenses soared by 10947.03% in 2023, and later tumbled by 9846.15% in 2025.
  • Protalix BioTherapeutics' Interest Expenses (Quarter) stood at $908000.0 in 2021, then decreased by 28.41% to $650000.0 in 2022, then increased by 19.08% to $774000.0 in 2023, then tumbled by 94.7% to $41000.0 in 2024, then tumbled by 85.37% to $6000.0 in 2025.
  • Its Interest Expenses was $6000.0 in Q1 2025, compared to $41000.0 in Q4 2024 and $260000.0 in Q3 2024.